Compare NIU & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | CDXS |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 154.4M |
| IPO Year | 2018 | 2008 |
| Metric | NIU | CDXS |
|---|---|---|
| Price | $1.89 | $1.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.55 | ★ $6.14 |
| AVG Volume (30 Days) | 181.7K | ★ 717.5K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | $20.29 | $4.97 |
| Revenue Next Year | $22.76 | $18.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $1.79 | $0.96 |
| 52 Week High | $4.58 | $2.98 |
| Indicator | NIU | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 47.27 |
| Support Level | $1.81 | $1.27 |
| Resistance Level | $2.04 | $1.77 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 48.15 | 57.78 |
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.